A trial of a dual-target CAR-T therapy for blood cancers
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a new treatment that uses a virus to make your own immune cells attack two targets on cancer cells. It is for people with B-cell blood cancers that have come back or not responded to other treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have a type of blood cancer like non-Hodgkin lymphoma or chronic lymphocytic leukemia that has returned or not improved with treatment.
- You are well enough to carry out daily activities (ECOG score 0 or 1).
- You have at least one tumor that can be measured on scans.
- You have not had certain other cancer treatments too recently.
- You are not pregnant or breastfeeding, and you do not have active hepatitis or HIV.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new type of CAR-T cell therapy that targets two proteins (CD19 and CD20) on cancer cells. It is for people with certain B-cell blood cancers that have come back or not responded to treatment, and aims to see if this therapy can help control the cancer.
This trial tests a new type of cell therapy that targets two markers (CD19 and CD20) on lymphoma cells. It is for patients whose lymphoma has come back or has not responded to standard treatments.
This trial tests a new type of CAR-T therapy (a treatment that uses your own immune cells, genetically changed to attack cancer) that targets a protein called CD20 found on some blood cancer cells. It's for people with B-cell lymphoma or lymphocytic leukemia who have already had other treatments and need a new option.
This trial tests a new type of immunotherapy that uses your own immune cells engineered to recognize two cancer targets (CD19 and CD22) to treat B-cell blood cancers that have come back or not responded to standard treatments. It may offer a treatment option when other therapies have stopped working.
This trial tests a new kind of cell therapy that uses immune cells, called CAR-T cells, that are engineered to find and attack lymphoma cells showing CD19 or CD20 markers. It aims to see if this dual-target approach is safe and effective for people with lymphoma that has relapsed or not responded to previous treatments.
This study tests a new type of cell therapy called CAR-T cells that are designed to target two different proteins on cancer cells. These cells are made from your own immune cells, trained in the lab, and then put back into your body to fight blood cancers that have come back or stopped responding to previous treatments.
Hear when a new Relapsed/Refractory B-cell Malignancies trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.